Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 3Recruiting 2Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 5Breast Neoplasms 3Prostatic Neoplasms 2Fallopian Tube Neoplasms 2Uterine Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1MMR-D/MSI-H Colorectal Cancers 1Lymphoma 1Leiomyosarcoma 1Glioblastoma 1Endometrial Neoplasms 1Cystadenocarcinoma, Serous 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Radiosurgery 7Oxaliplatin 7Docetaxel 7Paclitaxel 5Fluorouracil 5Nivolumab 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Carboplatin 4Capecitabine 4Trastuzumab 3Radiotherapy 3Radiation 3Leucovorin 3Erlotinib Hydrochloride 3Cyclophosphamide 3Cetuximab 3Bevacizumab 3spartalizumab 2sipuleucel-T 2repotrectinib 2pembrolizumab 2pazopanib 2orteronel 2fludarabine 2atezolizumab 2aldesleukin 2Temozolomide 2Surveys and Questionnaires 2Sunitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neoplasm Metastasis × niraparib × Clear all
NCT04895046 2022-06-29

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

Hoosier Cancer Research Network

Phase 2 Withdrawn
Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡